Clinical trial
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of…
NCT00084682 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00084682 |
|---|---|
| Title | Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| Official title | A Phase II Study of Single Agent Depsipeptide (FK228; NSC 630176; IND 51,810) in Patients With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx |
| Intervention type | Drug |
| Interventions | romidepsin |
| Enrollment | 14 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Mar 1, 2012 |
| First posted | Jun 11, 2004 |
| Last update posted | Mar 5, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: